· Published by Health Canada · Official notice
Notice about Health Canada advisories
June 23, 2004
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Pharmacy and Psychiatry and other involved professional staff and post this NOTICE in your institution.
Subject: Monitoring of patients taking clozapine
The Marketed Health Products Directorate (MHPD) and the Therapeutic Products Directorate (TPD) would like to draw your attention to important upcoming revisions to the Product Monograph of all clozapine products marketed in Canada. These revisions will strengthen the labeling and address ongoing issues around patient consent for the sharing of information between registries, considered important due to the well-known risk of agranulocytosis associated with clozapine use.
Revisions to clozapine Product Monographs will emphasize the following:
Patients on clozapine and their treating physicians and dispensing pharmacists have to be enrolled in registries, which are currently specific to each market authorization holder. Patients must undergo regular haematological tests to monitor their total white blood-cell and absolute neutrophil counts. Between 1991 and 2003, clozapine was distributed by a single manufacturer, and patients were monitored by this manufacturer's specific registry. The introduction of generic clozapine in the last year has led to the establishment of other registries.
Health Canada is taking the following steps to ensure the safe use and continuous monitoring of patients taking clozapine in Canada:
The implementation of these steps will permit the achievement of a more efficient network of independent registries, and therefore improve the continuity of care of patients treated with clozapine.
The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of serious and/or unexpected adverse reactions in patients receiving clozapine should be reported to Health Canada at the following address:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
For other inquiries: please refer to contact information.
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.